<--- Back to Details
First PageDocument Content
Stomach cancer / Esophageal cancer / Gastric lymphoma / Adjuvant therapy / Chemotherapy / Matuzumab / Colorectal cancer / Oxaliplatin / Cyclacel / Medicine / Gastrointestinal cancer / Oncology
Date: 2014-03-30 02:19:49
Stomach cancer
Esophageal cancer
Gastric lymphoma
Adjuvant therapy
Chemotherapy
Matuzumab
Colorectal cancer
Oxaliplatin
Cyclacel
Medicine
Gastrointestinal cancer
Oncology

Gastrointestinal Oncology Introduction The Gastrointestinal Oncology Division currently focuses on chemotherapy with or without radiation therapy against gastrointestinal malignancies. We treat many patients practically,

Add to Reading List

Source URL: www.ncc.go.jp

Download Document from Source Website

File Size: 27,29 KB

Share Document on Facebook

Similar Documents

Ellenoff Grossman & Schole LLP 2015 Representative Registered Direct Transactions Areas of Practice Include: CORPORATE AND

Ellenoff Grossman & Schole LLP 2015 Representative Registered Direct Transactions Areas of Practice Include: CORPORATE AND

DocID: 1raK7 - View Document

Gastrointestinal Oncology Introduction The Gastrointestinal Oncology Division currently focuses on chemotherapy with or without radiation therapy against gastrointestinal malignancies. We treat many patients practically,

Gastrointestinal Oncology Introduction The Gastrointestinal Oncology Division currently focuses on chemotherapy with or without radiation therapy against gastrointestinal malignancies. We treat many patients practically,

DocID: 1b292 - View Document

PRESS RELEASE PRESS RELEASE ERYTECH announces management change

PRESS RELEASE PRESS RELEASE ERYTECH announces management change

DocID: 1anqj - View Document

BIOTOPics  DRUG DISCOVERY AND DEVELOPMENT POTENTIALS – PROFILES – PERSPECTIVES Journal of Biotechnology in Berlin-Brandenburg

BIOTOPics DRUG DISCOVERY AND DEVELOPMENT POTENTIALS – PROFILES – PERSPECTIVES Journal of Biotechnology in Berlin-Brandenburg

DocID: 19CXC - View Document

The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe

The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe

DocID: 19brv - View Document